Activity of psoralen-functionalized nanoscintillators against cancer cells upon X-ray excitation.

Published

Journal Article

We report development of a nanoparticle-based, X-ray-activated anticancer "nanodrug" composed of yttrium oxide (Y(2)O(3)) nanoscintillators, a fragment of the HIV-1 TAT peptide, and psoralen. In this formulation, X-ray radiation is absorbed by the Y(2)O(3) nanoscintillators, which then emit UVA light. Absorption of UVA photons by nanoparticle-tethered psoralen has the potential to cross-link adenine and thymine residues in DNA. UVA-induced cross-linking by free psoralen upon activation with UVA light has previously been shown to cause apoptosis in vitro and an immunogenic response in vivo. Studies using the PC-3 human prostate cancer cell line demonstrate that X-ray excitation of these psoralen-functionalized Y(2)O(3) nanoscintillators yields concentration-dependent reductions in cell number when compared to control cultures containing psoralen-free Y(2)O(3) nanoscintillators.

Full Text

Duke Authors

Cited Authors

  • Scaffidi, JP; Gregas, MK; Lauly, B; Zhang, Y; Vo-Dinh, T

Published Date

  • June 2011

Published In

Volume / Issue

  • 5 / 6

Start / End Page

  • 4679 - 4687

PubMed ID

  • 21553850

Pubmed Central ID

  • 21553850

Electronic International Standard Serial Number (EISSN)

  • 1936-086X

International Standard Serial Number (ISSN)

  • 1936-0851

Digital Object Identifier (DOI)

  • 10.1021/nn200511m

Language

  • eng